Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum

European Journal of Pharmaceutical Sciences

Volumn 46, Issue 5, 2012, Pages 530-536

  Seidegård, Janeric ^a   Nyberg, Lars ^b   Borgå, Olof ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b Bioperm AB   (Sweden)

Author keywords

Budesonide; CYP3A; First pass metabolism; Intubation; Local administration; Small intestine

Indexed keywords

BUDESONIDE; KETOCONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG LABELING; FIRST PASS EFFECT; HUMAN; JEJUNUM; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MUCOSA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BUDESONIDE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL MUCOSA; JEJUNUM; KETOCONAZOLE; LIVER; MALE; SWEDEN; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84861199898     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.04.005     Document Type: Article

References (30)

1. D.G. Bailey, J.M.O. Arnold, J.R. Bend, L.T. Tran, and J.D. Spence Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation Br. J. Clin. Pharmacol. 40 1995 135 140
2. M.P. Ducharme, L.H. Warbasse, and D.J. Edwards Disposition of intravenous and oral cyclosporine after administration with grapefruit juice Clin. Pharmacol. Ther. 57 1995 485 491
3. S. Edsbäcker, B. Bengtsson, P. Larsson, P. Lundin, Å. Nilsson, J. Ulmius, and P. Wollmer A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort™) capsules Aliment Pharmacol. Ther. 17 2003 525 536
4. S. Edsbäcker, and T. Andersson Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease Clin. Pharmacokinet. 43 2004 803 821
5. W.L. Fitch, T. Tran, M. Young, L. Liu, and Y. Chen Revisiting the metabolism of ketoconazole using accurate mass Drug Metab. Lett. 3 2009 191 198
6. M.F. Fromm, D. Busse, H.K. Kroemer, and M. Eichelbaum Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin Hepatology 24 1996 796 801
7. D.J. Greenblatt, L.L. von Moltke, J.S. Harmatz, G. Chen, J.L. Weemhoff, C. Jen, C.J. Kelley, B.W. LeDuc, and M.A. Zinny Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice Clin. Pharmacol. Ther. 74 2003 121 129
8. S.D. Hall, K.E. Thummel, P.B. Watkins, K.S. Lown, L.Z. Benet, M.F. Paine, R.R. Mayo, D.K. Turgeon, D.G. Bailey, R.J. Fontana, and S.A. Wrighton Molecular and physical mechanisms of first-pass extraction Drug. Metab. Dispos. 27 1999 161 166
9. M.F. Hebert, J.P. Roberts, T. Prueksaritanont, and L.Z. Benet Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction Clin. Pharmacol. Ther. 52 1992 453 457
10. N. Holtbecker, M.F. Fromm, H.K. Kroemer, E.E. Ohnhaus, and H. Heidemann The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism Drug Metab. Dispos. 24 1996 1121 1123
11. G. Jönsson, A. ström, and P. Andersson Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver Drug Metab. Dispos. 23 1995 137 142
12. M. Kato Intestinal first-pass metabolism of CYP3A4 substrates Drug Metab. Pharmacokinet. 23 2008 87 94
13. J.C. Kolars, W.M. Awni, R.M. Merion, and P.B. Watkins First-pass metabolism of cyclosporin by the gut Lancet 338 1991 1488 1490
14. J.C. Kolars, P. Schmiedlin-Ren, J.D. Schuetz, C. Fang, and P.B. Watkins Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes J. Clin. Invest. 90 1992 1871 1878
15. H.H.T. Kupferschmidt, H.R. Ha, W.H. Ziegler, P.J. Meier, and S. Krähenbuhl Interaction between grapefruit juice and midazolam in humans Clin. Pharmacol. Ther. 58 1995 20 28
16. J.J. Lilja, K.T. Kivistö, and P.J. Neuvonen Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastin Clin. Pharmacol. Ther. 68 2000 384 390
17. K.S. Lown, J.C. Kolars, K.E. Thummel, J.L. Barnett, K.L. Kunze, S.A. Wrighton, and P.B. Watkins Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test Drug Metab. Dispos. 22 1994 947 955
18. A. Melander, and A. McLean Influence of food intake on presystemic clearance of drugs Clin. Pharmacokinet. 8 1983 286 296
19. L. Nyberg, W. Månsson, B. Abrahamsson, J. Seidegård, and O. Borgå A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies Eur. J. Pharm. Sci. 30 2007 432 440
20. M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, C.L. Marsh, J.P. McVicar, D.M. Barr, B.S. Gillies, and K.E. Thummel First-pass metabolism of midazolam by the human intestine Clin. Pharmacol. Ther. 60 1996 14 24
21. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, and K.E. Thummel Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 1997 1552 1562
22. Å. Ryrfeldt, P. Andersson, S. Edsbäcker, M. Tönnesson, D. Davies, and R. Pauwels Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid Eur. J. Respir. Dis. Suppl. 122 1982 86 95
23. J. Seidegård, L. Nyberg, and O. Borgå Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole Eur. J. Pharm. Sci. 35 2008 264 270
24. J. Seidegård, G. Randvall, L. Nyberg, and O. Borgå Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations Pharmazie 64 2009 461 465
25. D.D. Shen, K.L. Kunze, and K.E. Thummel Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction Adv. Drug. Deliv. Rev. 15 1997 99 127
26. K.E. Thummel, D. O'Shea, M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, and G.R. Wilkinson Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism Clin. Pharmacol. Ther. 59 1996 491 502
27. M.L. Veronese, L.P. Gillen, J.P. Burke, E.P. Dorval, W.W. Hauck, E. Pequignot, S.A. Waldman, and H.E. Greenberg Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice J. Clin. Pharmacol. 43 2003 831 839
28. P.B. Watkins The barrier function of CYP3A4 and P-glycoprotein in the small bowel Adv. Drug Deliv. Rev. 27 1997 161 170
29. C.-Y. Wu, L.Z. Benet, M.F. Hebert, S.K. Gupta, M. Rowland, D.Y. Gomez, and W.J. Wacher Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine Clin. Pharmacol. Ther. 58 1995 492 497
30. Q.-Y. Zhang, D. Dunbar, A. Ostrowska, S. Zeisloft, J. Yang, and L.S. Kaminsky Characterization of human small intestinal cytochromes P-450 Drug. Metab. Dispos. 27 1999 804 809